|
Jul 9
|
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
|
|
Jul 9
|
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
|
|
Dec 20
|
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
|
|
Nov 8
|
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
|
|
Nov 6
|
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
|
|
Sep 22
|
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
|
|
Sep 21
|
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
|
|
Sep 19
|
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
|
|
Jun 29
|
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
|
|
Jun 28
|
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
|
|
Jun 26
|
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
|
|
Jun 23
|
Life Science Investor Forum: Presentations Now Available for Online Viewing
|
|
Apr 27
|
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
|
|
Apr 25
|
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
|